Late-Stage Active Oncology Drug Developers | An Overview
June 22, 2024
. SERINE / THEONINE KINASE INHIBITORS 1. BRAF/MEK/ERK Inhibitors 2. CDK Inhibitors 3. PI3K/AKT/mTOR Inhibitors Check Also KINASE INHIBITORS -...
. NON-RECEPTOR TYROSINE KINASE INHIBITORS 1. Bcr-Abl1 Inhibitors 2. JAK Inhibitors 3. BTK Inhibitors Check Also KINASE INHIBITORS - An...
Protein kinases are the enzymes that catalyzes the transfer of γ-phosphate group from ATP to protein residues containing hydroxyl groups...
Protein kinases are the enzymes that catalyzes the transfer of γ-phosphate group from ATP to protein residues containing hydroxyl groups...
First cancer targeting tyrosine kinase inhibitor imatinib was approved to enter the market by the US Food and Drug Administration...
First cancer targeting tyrosine kinase inhibitor imatinib was approved to enter the market by the US Food and Drug Administration...
Small Molecule drug treatment is one of the main approaches in treating cancer. Until recent years, chemotherapy was the only...
Small- molecule kinase inhibitors have the potential for broad efficacy, convenience and tissue penetrance, and thus often offer important advantages...
NK is the abbreviation of Natural Killer, and its Chinese name is natural killer cell. Due to the pan-specific...
Read moreupdated.. easy.. precise... complete...
Presenting filtered comprehensive information. Gain more insights on emerging bio-business, frame strategies, grow faster & better connect with biological science community.
LEARN MORE »
Developed by OmicsX. The entirety of this site is protected by copyright © 2010–2021 HH BioTechnologies Private Ltd.
Developed by OmicsX. The entirety of this site is protected by copyright © 2010–2021 HH BioTechnologies Private Ltd.